Tecovirimat SIGA Under Scrutiny: European Regulators Review Efficacy Amidst Clinical Trial Data

London, UK – Tecovirimat SIGA, an antiviral medication approved for the treatment of mpox, is currently undergoing a complete review by the European Medicines Agency (EMA). the review, initiated at the request of the European Commission, aims to reassess the drug’s benefit-risk balance in light of preliminary findings from recent clinical trials.

Mpox, a viral zoonotic disease, can present with a range of symptoms including fever, headache, chills, physical weakness, lymph node swelling, back pain, and muscle aches. A characteristic feature is a distinct, fast-spreading papular rash that progresses to fluid-filled vesicles, often appearing on the skin and in mucosal areas such as the mouth, nose, throat, and digestive tract. While mild-to-moderate cases typically resolve within 2-4 weeks, some individuals may develop permanent scarring. The case fatality rate for mpox outbreaks can range from 0% to 11%, with immunocompromised individuals, including those with HIV infection or AIDS, facing a higher risk of severe disease.

Exceptional Circumstances Approval and Post-Authorization Review

Tecovirimat SIGA was initially granted approval under “exceptional circumstances” provisions. this decision was based on pharmacodynamic and pharmacokinetic studies, as human trials were not available due to the rarity and sporadic nature of the disease.A condition of this authorization mandates that the marketing company provide an annual update on the drug’s benefits and risks.The EMA’s current review is a post-authorization procedure, a scientific assessment conducted on behalf of the EU to address concerns regarding the safety or benefit-risk balance of a medicine.

Clinical Trial Findings Raise Efficacy Questions

The EMA’s review is informed by the preliminary results of two critically important clinical trials.

PALM007 Trial: No Significant Reduction in Lesion Duration

The PALM007 trial, a randomized, placebo-controlled study conducted in the democratic Republic of the Congo (DRC), involved 597 children and adults diagnosed with laboratory-confirmed clade I mpox. Published in The New England Journal of Medicine, the trial’s preliminary results indicated that tecovirimat did not significantly reduce the duration of mpox lesions, with a median time to resolution of 7 days for the treated group compared to 8 days for the placebo group. The overall mortality rate in the trial was 1.6%, which was attributed to the high-quality supportive care and hospitalization provided within the study setting, rather than the drug’s direct impact.

STOMP Trial: Similar Outcomes for lesion Resolution

The STOMP trial, which included participants from multiple countries with mild-to-moderate laboratory-confirmed or presumptive clade II mpox, yielded similar findings.In this study, the active drug also failed to demonstrate efficacy in accelerating the time to resolution of skin and mucosal lesions when compared to placebo.

further analyses from the ongoing UNITY study and other recently completed trials are still pending. These additional data are expected to provide further insights and will be crucial in informing the EMA’s final assessment of Tecovirimat SIGA’s efficacy and overall benefit-risk profile.Dr Sheena Meredith is an established medical writer, editor, and consultant in healthcare communications, with extensive experience writing for medical professionals and the general public. she is qualified in medicine and in law and medical ethics.